The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The real-time PCR-based test runs on the BD Max system and comes in a single tube that snaps into the BD MAX extraction cartridge.
The test runs on the company's Solana instrument, which can process up to 12 patient samples in a 45-minute run.
The investment bank said it has heard positive feedback from early adopters in Europe of GenMark's ePlex system and respiratory panel.
The Alere flu test detected fewer cases of influenza A in a recent study, which researchers attributed to low viral loads.
Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.